Nobilis Therapeutics
  • Home
  • Company
    • About
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • NBTX-001
    • Science behind NBTX-001
    • Clinical Development Program
    • Intellectual property
  • Inhalation Devices
    • Zephyrus™ Device
  • Contact Us
Select Page

Nobilis Therapeutics Signs Exclusive License Agreement with Harvard University for PTSD Treatment

by nobilistx | Mar 8, 2016 | Uncategorized | 0 comments

http://www.marketwired.com/press-release/nobilis-therapeutics-signs-exclusive-license-agreement-with-harvard-university-ptsd-2109502.htm

Nobilis Therapeutics Signs Exclusive License Agreement with Harvard University for PTSD Treatment

Submit a Comment Cancel reply

You must be logged in to post a comment.

News

  • Nobilis Therapeutics Enters into Collaboration with The Linde Group to Support Its Clinical Research Program to Study a drug/device combination for Treatment of PTSD and Other CNS Disorders. January 10, 2019
  • Nobilis Therapeutics Announces IND Filing for a Phase IIb Clinical Trial of NBTX-001 Drug/Device Combination for Treatment of Posttraumatic Stress Disorder January 6, 2019
  • Nobilis Collaborates on a Study of Argon Use to Treat Diabetic Wounds, Publishes Positive Results January 2, 2019
  • Meet us at JP Morgan Healthcare Conference on Jan 7-10 in San Francisco. We have a lot of exciting updates! December 20, 2018
  • Nobilis Therapeutics just published an article “Xenon as Promising Treatment for Patients with PTSD: Case Report, Justification of Approach and Review of Literature” in Annals of Psychiatry and Mental Health. November 28, 2018

Recent Posts

  • Nobilis Therapeutics Enters into Collaboration with The Linde Group to Support Its Clinical Research Program to Study a drug/device combination for Treatment of PTSD and Other CNS Disorders.
  • Nobilis Therapeutics Announces IND Filing for a Phase IIb Clinical Trial of NBTX-001 Drug/Device Combination for Treatment of Posttraumatic Stress Disorder
  • Nobilis Collaborates on a Study of Argon Use to Treat Diabetic Wounds, Publishes Positive Results
  • Meet us at JP Morgan Healthcare Conference on Jan 7-10 in San Francisco. We have a lot of exciting updates!
  • Nobilis Therapeutics just published an article “Xenon as Promising Treatment for Patients with PTSD: Case Report, Justification of Approach and Review of Literature” in Annals of Psychiatry and Mental Health.

Recent Comments

    Archives

    • January 2019
    • December 2018
    • November 2018
    • August 2018
    • June 2018
    • May 2018
    • February 2018
    • January 2018
    • December 2017
    • October 2017
    • June 2017
    • May 2017
    • April 2016
    • March 2016
    • January 2016

    Categories

    • Uncategorized

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org
    • Facebook
    • Twitter
    • Google
    • RSS

    Designed by GO | Powered by GOs